医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Craif, Inc., a Startup Developing Urine Test Kits for Higher Possibility of the Early Detection of Cancer

2024年03月05日 AM10:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd.(TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University that develops urine test kits that enhance the possibility of the early detection of cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240304365301/en/

miSignal cancer risk test kit (Photo: Business Wire)

miSignal cancer risk test kit (Photo: Business Wire)

With its expertise in nanometer level processing technology in the bioscience field, Craif develops and sells test kits that can easily and highly sensitively detect the risks of seven types of cancer, including pancreatic and lung cancer, as early as cancer stage 1. These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect. Higher accuracy is achieved in combination with the tests using AI analysis.

Toyoda Gosei has been developing products and collaborating with other companies in the field of preventive medicine to tackle social issues brought on by increased longevity. The company will continue to cultivate healthcare businesses through activities to promote and maintain the health of its employees and those of its business partners.

1 Investment made in February 2024, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.

2 The amount and type of miRNA contained in urine differs depending on the type of cancer and its progression. This makes miRNA contribute to the detection of the cancer risk.

Outline of Craif, Inc.

Name

Craif, Inc.

Location

5F Hongo ITP Office, 2-25-7 Yushima, Bunkyo-ku, Tokyo, Japan

CEO

Ryuichi Onose

Established

May 2018

Capital

JPY 100 million (as of March 20, 2023)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240304365301/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Public Relations

inquiry@mlist.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
  • JCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal Disorders
  • Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
  • ベイジーン、アーロン・ローゼンバーグ氏を最高財務責任者に任命
  • ICH and CDISC Collaborate to Support the Maintenance and Governance Process for ICH M11 Controlled Terminology